July 24 (Bloomberg) -- Aeterna Zentaris Inc. rose the most in almost three weeks after the biotech company said it would ask the U.S. Food and Drug Administration to fast-track the approval process for its proposed test to diagnose growth hormone deficiency.
Aeterna, based in Quebec City, jumped 7 percent to 46 Canadian cents by 4 p.m. in Toronto, its largest single-day gain since July 5.
The FDA is due to respond to the request within 60 days, Aeterna said today in a statement. Aeterna expects to complete its submission for the AEZS-130 diagnostic test in the first quarter of 2013 if the FDA grants fast-track status, the company said.
To contact the reporter on this story: Frederic Tomesco in Montreal at email@example.com
To contact the editor responsible for this story: Ed Dufner at firstname.lastname@example.org